Overall we show that the transcriptional activity of ELF5 suppresses estrogen action in luminal breast cancer, enhances expression of the basal phenotype, specifies patterns of gene expression distinguishing molecular subtype, and exerts a proliferative influence that can be modified to allow luminal breast cancer to become resistant to antiestrogen treatment. This evidence concerns the gene ELF5 and breast cancer.